US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Change in the number of shares and votes in AddLife AB

According to AddLife AB, org. no. 556995–8126, (“AddLife”) Articles of Association, the owner of Class A shares has the right to request that the share be converted into Class B shares. At the request of shareholders, 37,000 Class A shares were converted to 37,000 Class B shares. Following the conversion, the total number of shares and votes in AddLife as of October 31, 2024, amounts to 122,450,250 shares and 163,605,414 votes, respectively. 4,572,796 of these shares are Class A shares, representing 45,727,960 votes, and 117,877,454 are Class B shares, representing 117,877,454 votes.

Interim Report 1 January – 30 September 2024

Organic growth and stable margin while profitability improvement initiatives are progressing "Continued organic growth and stable margin in the third quarter - a quarter that is normally somewhat weaker seasonally. The work on profitability improvements is progressing according to plan." Fredrik Dalborg, President and CEO AddLife´s interim report for Q3 2024 is now available online at the company website. The interim report can be downloaded in pdf version. Visit reports-en.add.life/interim-report-q3-2024 1 JULY – 30 SEPTEMBER 2024 (3 MONTHS) · Net sales increased by 1% to

Interim Report 1 January – 30 June 2024

Good growth in both Business Areas and continued profitability improvement "The companies within AddLife showed strong performance development during the quarter. In Labtech, sales growth recovered as expected and margins remained stable. Sales growth in Medtech was good and margins improved partly driven by restructuring efforts that are now yielding clear results. Cash flow improved significantly and after the end of the quarter, an acquisition was made in line with our updated long-term strategy."Fredrik Dalborg, President and CEO AddLife´s interim report for Q2 2024 is now

AddLife acquires BonsaiLab

AddLife acquires BonsaiLab, a leading Spanish distributor in the field of cell and molecular biology. The company, with current revenues of EUR 8 m, has operations in Spain and Portugal and will be included in AddLife’s business area Labtech. BonsaiLab is a biotech company providing a portfolio of market-leading instruments and consumables in the field of cell and molecular biology. The company’s offering includes cutting-edge technology products, analytical solutions, and services for genomics laboratories in Spain and Portugal, including products for next generation sequencing, genomic

Change in the number of shares and votes in AddLife AB

According to AddLife AB, org. no. 556995–8126, (“AddLife”) Articles of Association, the owner of Class A shares has the right to request that the share be converted into Class B shares. At the request of shareholders, 5,340 Class A shares were converted to 5,340 Class B shares. Following the conversion, the total number of shares and votes in AddLife as of June 28, 2024, amounts to 122,450,250 shares and 163,938,414 votes, respectively. 4,609,796 of these shares are Class A shares, representing 46,097,960 votes, and 117,840,454 are Class B shares, representing 117,840,454 votes. AddLife'

Annual General Meeting of AddLife AB 8 May 2024

Resolutions, including the following, were passed by the Annual General Meeting (“AGM”) and the ensuing statutory Board of Directors Meeting of AddLife AB (the “Company”) held on 8 May 2024. Adoption of the Profit and Loss Statements and the Balance SheetsThe AGM resolved to adopt the Profit and Loss Statement and the Balance Sheet for the Company as well as the Consolidated Profit and Loss Statement and the Consolidated Balance Sheet for the Group. DividendA dividend of SEK 0.50 per share, irrespectively of class of shares, was declared. Record date for the dividend was confirmed

Interim Report 1 January – 31 March 2024

Positive profitability trend driven by Medtech "During the quarter, profitability strengthened in line with our priorities and organic sales increased by 4%. Labtech's sales performance was temporarily weaker, but the companies were largely able to defend their margins. Medtech delivered strong growth and it is gratifying to see a gradual improvement in profitability, driven in part by implemented improvement measures."Fredrik Dalborg, President and CEO AddLife´s interim report for Q1 2024 is now available online at the company website. The interim report can be downloaded in pdf

AddLife´s Annual Report for 2023 is now published

AddLife´s Annual Report for 2023 is now available online at the company website. The Annual Report can be downloaded in pdf version.Visit https://reports-en.add.life/annual-report-2023/addlife-2023/ Stockholm, April 5, 2024 AddLife AB (publ)AddLife AB, Box 3145, 103 62 StockholmTel +46 (0)8-420 038 30www.add.lifeinfo@add.life For further information, please contact:Fredrik Dalborg, VD, fredrik.dalborg@add.life, +46 70 516 09 01Christina Rubenhag, CFO, christina.rubenhag@add.life, +46 70 546 72 22 AddLife is an independent European player in Life Science that offers

Notice to attend the Annual General Meeting of AddLife AB (publ)

The shareholders of AddLife AB (publ) (the “Company”), reg. no 556995-8126, are hereby given notice to attend the Annual General Meeting to be held at 4:00 p.m. CEST, Wednesday, 8 May 2024, at World Trade Center, room New York, Klarabergsviadukten 70, Stockholm, Sweden. Registration for the meeting commences at 3:30 p.m. CEST.This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail. NOTICE OF PARTICIPATION        Shareholders who wish to participate in the proceedings of the Annual General

Year-end report 1 January – 31 December 2023

Strong cash flow and significant actions to improve profitability within Medtech "Demand is healthy in the markets and segments where AddLife's companies operate. We can now summarize 2023 as a year with historically strong organic growth of 10%. In the fourth quarter, cash flow improved significantly and net debt decreased by approximately SEK 400 m. Labtech's profitability was high and in Medtech, profitability was generally good, but weighed down by AddVision and Homecare, where we are now implementing significant actions to improve profitability."Fredrik Dalborg, President and CEO

AddLife continues its review of Homecare

Addlife has decided to initiate trade union negotiations regarding a planned closure of the subsidiary Camanio and its development project relating to safety alarms. This is a result of the previously announced evaluation of the Homecare development initiatives. All employees have therefore been given notice of probable termination of employment. In conjunction with the closure of the company Camanio, Addlife will report an impairment loss on related assets totalling SEK 100 million in the fourth quarter of 2023. Camanio’s development project relating to safety alarms has entailed an

Interim Report 1 January – 30 September 2023

Continued strong organic growth in both business areas "AddLife's growth plan is working well and, after a period of COVID-19 and acquisition-driven growth, we are now seeing robust organic growth. Profitability has improved and we have implemented a number of measures that are expected to support a positive profitability trend moving forward. The activities to improve cash flow have been successful and we are excited that we have completed an add-on acquisition in the quarter."Fredrik Dalborg, President and CEO AddLife´s interim report for Q3 2023 is now available online at the

AddLife reiterates its financial targets and identifies prioritized growth segments

Today from 8:30 am CEST AddLife is hosting a Capital Markets Day. The event can be followed using the following link: https://tv.streamfabriken.com/addlife-capital-markets-day-2023 During the Capital Markets Day today AddLife will be presenting an overview of it’s business model, the current state and priorities of the business. A review of financials and balance sheet will be provided, including ambition and action for debt reduction. There will also be presentations from two companies within the Group as well as an overview of the strategy. The strategy is built on AddLife’s

Invitation to AddLife’ s Capital Markets Day 15 Sept 2023

AddLife is pleased to invite analysts, investors and financial media to a Capital Markets Day on Friday 15 Sept 2023 at 8:30-12:00. The Capital Markets Day will be held at Studio Puck, Kommendörsgatan 24, Stockholm. The Registrations starts at 8:00. The purpose of the Capital Markets Day is to give insights into AddLife’s business model, selected companies in the Group as well as providing more context and detail regarding AddLife’s market and strategy. In addition, there will be an opportunity to meet with members of AddLife's management team. Presentations will be held by Fredrik

Interim Report 1 January – 30 June 2023

Continued strong growth"Increased commercial activity and new development initiatives create growth and we see many opportunities todevelop the business further."Fredrik Dalborg, President and CEO AddLife´s interim report for Q2 2023 is now available online at the company website. The interim report can be downloaded in pdf version. Visit reports-en.add.life/interim-report-q2-2023 1 APRIL – 30 JUNE 2023 (3 MONTHS) · Net sales increased by 14% to SEK 2,365 m (2,079). The COVID-19 related sales decreased to 0 m (36) and the organic growth excluding, COVID-19 related sales and

Annual General Meeting of AddLife AB 4 May 2023

Resolutions, including the following, were passed by the Annual General Meeting (“AGM”) and the ensuing statutory Board of Directors Meeting of AddLife AB (the “Company”) held on 4 May 2023. DividendA dividend of SEK 1.20 per share, irrespectively of class of shares, was declared. Record date for the dividend was confirmed to be Monday, 8 May 2023. The dividend is expected to be remitted by Euroclear Sweden AB on Thursday, 11 May 2023. Adoption of the Profit and Loss Statements and the Balance SheetsThe AGM resolved to adopt the Profit and Loss Statement and the Balance Sheet for

Interim Report 1 January – 31 March 2023

Strong organic growth in both business areas "Strong organic growth of 12 percent in the quarter reflects strong demand for our products and services. We are well-positioned for the recovery that is now taking place in health care and is expected to continue for a long time to come."Fredrik Dalborg, CEO AddLife AddLife´s interim report for Q1 2023 is now available online at the company website. The interim report can be downloaded in pdf version. Visit reports-en.add.life/interim-report-q1-2023 1 JANUARY – 31 MARCH 2023 (3 MONTHS) · Net sales decreased by 5 percent to SEK 2,

AddLife´s Annual Report for 2022 is now published

AddLife´s Annual Report for 2022 is now available online at the company website. The Annual Report can be downloaded in pdf version.Visit reports-en.add.life/annual-report-2022/addlife-2022/  Stockholm, March 31, 2023AddLife AB (publ)AddLife AB, Box 3145, SE-103 62 Stockholm, SwedenPhone +46 (0)8- 420 038 30www.add.lifeinfo@add.life For further information, please contact:  Fredrik Dalborg, VD, fredrik.dalborg@add.life, +46 70 516 09 01Christina Rubenhag, CFO, christina.rubenhag@add.life, +46 70 546 72 22 AddLife is an independent European player in Life Science

Notice to attend the Annual General Meeting of AddLife AB (publ)

The shareholders of AddLife AB (publ) (the “Company”), reg. no 556995-8126, are hereby given notice to attend the Annual General Meeting to be held at 4:00 p.m. CEST, Thursday, 4 May 2023, at World Trade Center, room New York, Klarabergsviadukten 70, Stockholm, Sweden. Registration for the meeting commences at 3:30 p.m. CEST.   NOTICE OF PARTICIPATION Shareholders who wish to participate in the proceedings of the Annual General Meeting must: · be entered in the shareholders’ register kept on behalf of the Company by Euroclear Sweden AB as of the record date, Tuesday 25 April

AddLife strengthens the organization for future growth

AddLife develops the organization to take advantage of future growth opportunities and strengthens the support to the portfolio companies by adding internally recruited resources with solid international operational experience. "AddLife has grown significantly in recent years and acquired several major companies in Europe within multiple new segments. With this new and strengthened position, AddLife has gained access to many new growth opportunities and has also added new and highly competent international teams in the various companies. AddLife is now developing an organization for

Year-End Report 1 January – 31 December 2022

Increased organic growth in both business areas AddLife´s year-end report for Q4 2022 is now available online at the company website. The year-end report can be downloaded in pdf version. Visit https://reports-en.add.life/year-end-report-q4-2022 1 OCTOBER – 31 DECEMBER 2022 (3 MONTHS) · Net sales increased by 9 percent to SEK 2,326m (2,131), of which acquired growth amounted to 12 percent. The COVID-19 related net sales decreased by 82 percent. The organic growth, excluding net sales related to COVID-19, was 6 percent. · EBITA amounted to SEK 258m (329), corresponding to an

Repurchase own shares

AddLife has today repurchased own shares of 110,000 Class B shares at a price of SEK 104.05 per share. The purchase has been made via Nasdaq Stockholm at the price interval prevailing. The repurchase is carried out in accordance with the Annual General Meeting's authorization to the Board to acquire shares in the Company. The purpose of the repurchase is to cover the Company’s obligations under previously resolved incentive programs and to make possible future acquisitions of companies and businesses with payment in the form of shares in the Company. AddLife AB holds after the

Interim Report 1 January – 30 September 2022

Growth in a changing market AddLife´s interim report for Q3 2022 is now available online at the company website. The interim report can be downloaded in pdf version. Visit reports-en.add.life/interim-report-q3-2022  1 JULY – 30 SEPTEMBER 2022 (3 MONTHS) · Net sales increased by 14 percent to SEK 2,100m (1,850), of which acquired growth amounted to 16 percent. The COVID-19 related net sales decreased by 50 percent. The organic growth, excluding net sales related to COVID-19, was 2 percent. · EBITA increased by 1 percent

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media